Newsmeme!
Discover News you didn't know existed
Dose-dependent
News
Related Video News
No related video news stories found.
Related Videos
No related videos found.
Vitamin D may protect against placental infection: Study
Published December 2, 2008, 10:03 am, Nutraingredients.com
Researchers from the University of California, Los Angeles (UCLA) report that production of an antimicrobial protein called cathelicidin was stimulated when trophoblasts - cells that develop to make up a major part of the placenta – were exposed to the active form of vitamin D (1,25(OH)2D).
(AFX UK Focus) 2008-12-02 13:44 BRIEF-GSK gets positive phase 2b data on asthma drug
Published December 2, 2008, 6:04 am, Interactive Investor
LONDON, Dec 2 (Reuters) - GlaxoSmithKline Plc:
GSK and Theravance Announce Positive Phase 2b Results for LABA, '444 in the Horizon Asthma Development Programme
Published December 2, 2008, 5:00 am, Marketwire via Yahoo! Finance
GlaxoSmithKline Plc (GSK) and Theravance, Inc. today announced positive results from the phase 2b study of the novel, long-acting beta agonist GW642444 in patients with moderate to severe asthma. The study, which was designed to evaluate the efficacy of five doses of '444 administered once-daily for 4 weeks, showed dose dependent improvements in lung function. All but the two lowest doses of ...
XenoPort Reports Results from a Phase 2 Clinical Trial of XP19986 as a Treatment for the Symptoms of Gastroesophageal ...
Published December 2, 2008, 4:47 am, Centre Daily Times
XenoPort, Inc. (Nasdaq:XNPT) announced today top-line results from a Phase 2 clinical trial that examined the ability of XP19986 ( arbaclofen placarbil ) extended-release tablets to reduce symptoms experienced by subjects with gastroesophageal reflux disease, or GERD. The primary analysis comparing XP19986 to placebo did not reach statistical significance. However, pre-defined subgroup analyses ...
XenoPort Reports Results from a Phase 2 Clinical Trial of XP19986 as a Treatment for the Symptoms of Gastroesophageal ...
Published December 2, 2008, 4:30 am, Business Wire via Yahoo! Finance
SANTA CLARA, Calif.----XenoPort, Inc. announced today top-line results from a Phase 2 clinical trial that examined the ability of XP19986 extended-release tablets to reduce symptoms experienced by subjects with gastroesophageal reflux disease, or GERD.
Genaera starts trial of Trodusquemine in overweight and obese type 2 diabetes
Published December 2, 2008, 3:35 am, News-Medical-Net
Genaera Corporation has announced that dosing of subjects has begun in study MSI-1436C-102 (Study 102), the multiple ascending dose Phase 1b study of trodusquemine (MSI-1436) in overweight and obese type 2 diabetics.
First-Ever Human Trial of DNA-Based Immunotherapy Delivered Using Inovio Biomedical’s Electroporation Technology Shows ...
Published December 2, 2008, 3:32 am, Centre Daily Times
Inovio Biomedical Corporation (AMEX:INO), a leader in enabling the development of DNA vaccines using electroporation-based DNA delivery, announced today the final results of a Phase I clinical study demonstrating safe and effective treatment of metastatic melanoma in the first-in-man trial of a DNA-based therapy designed to express a therapeutic protein through in vivo delivery using ...
Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics
Published December 1, 2008, 6:00 am, PR Newswire via Yahoo! Finance
Genaera Corporation today announced that dosing of subjects has begun in study MSI-1436C-102 , the multiple ascending dose Phase 1b study of trodusquemine in overweight and obese type 2 diabetics.
Selenium supplements may boost heart health: Study
Published November 28, 2008, 7:31 am, Nutraingredients.com
Moreover, a plateau effect was observed after 12 weeks, regardless of the dose used.
GENFIT: Therapeutic Potential Of Gft505 Is Demonstrated In The Treatment Of Cardiovascular Risk Associated With ...
Published November 28, 2008, 7:11 am, Medical News Today
GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of research and development of drugs, focusing on early diagnosis and preventive treatment of cardiometabolic and neurodegenerative diseases, today communicate on important efficacy data in healthy volunteers
Related News Resources:
> HGH News
News Directory
Get started fast by using a pre-defined news directory category
|
Breaking News
and Top Stories |
Business
Earnings, Economy, Personal Finance, and Stock Markets |
Entertainment
Books, Celebrity, Fashion, Movies, Music, Television, and Theatre |
Health
Aging, Diseases, Medical Conditions, Medications, Sexual Health, and Weight Loss |
Politics
Congress, Supreme Court, and White House |
|
Science
Animals, Astronomy, Biotechnology, Space, and Weather |
Sports
Baseball, Basketball, Boxing, Football, Golf, Hockey, Motor Sports, Soccer, and Tennis |
Technology
Communications, Hardware, Internet, Personal Technology, and Software |
United States
and Crimes and Trials |
World
Africa, Antartica, Asia, Australia, Canada, Europe, Latin America, and Middle East |